Rearrangements of viral and human genomes at human papillomavirus integration events and their allele-specific impacts on cancer genome regulation

Vanessa L. Porter & Marco A. Marra et al. · 2025-04-14

Human papillomavirus (HPV) integration has been implicated in transforming HPV infection into cancer. To resolve genome dysregulation associated with HPV integration, we performed Oxford Nanopore Technologies long-read sequencing on 72 cervical cancer genomes from a Ugandan data set that was previously characterized using short-read sequencing. We find recurrent structural rearrangement patterns at HPV integration events, which we categorize as del(etion)-like, dup(lication)-like, translocation, multi-breakpoint, or repeat region integrations. Integrations involving amplified HPV–human concatemers, particularly multi-breakpoint events, frequently harbor heterogeneous forms and copy numbers of the viral genome. Transcriptionally active integrants are characterized by unmethylated regions in both the viral and human genomes downstream from the viral transcription start site, resulting in HPV–human fusion transcripts. In contrast, integrants without evidence of expression lack consistent methylation patterns. Furthermore, whereas transcriptional dysregulation is limited to genes within 200 kb of an HPV integrant, dysregulation of the human epigenome in the form of allelic differentially methylated regions affects megabase expanses of the genome, irrespective of the integrant's transcriptional status. By elucidating the structural, epigenetic, and allele-specific impacts of HPV integration, we provide insight into the role of integrated HPV in cervical cancer.

Funding

NCI NIH HHS

R01 CA262198

NCI NIH HHS

R21 CA241013

CIHR Frederick Banting and Charles Best Canada

GSD-152374

CIHR Frederick Banting and Charles Best Canada

GSD-164207

CIHR Frederick Banting and Charles Best Canada

FBD-187583

Canadian Institutes of Health Research

FRN-188098

Michael Smith Health Research BC

RT-2023-3168

Canadian Institutes for Health Research

FDN-143288

Canadian Institutes for Health Research

PJT-180410

NCI

R21CA241013

NCI

R01CA262198